bpc 157 clinical trial results I've worked with patients using BPC-157 as part of comprehensive recovery protocols for tendon injuries, joint discomfort, overuse injuries, exercise recovery, and gastrointestinal support. While the published research is still primarily preclinical BPC-157 10mg — Research Peptide
Description
In comparative pharmacokinetic assays, BPC-157 Arginate demonstrated roughly seven-fold higher oral bioavailability than the traditional BPC-157 Acetate form in rats
The study dose was gradually increased during the first 3 weeks of the study: Days 1-4: 1/6 of full dose Days 5-8: 2/6 of full dose Days 9-12: 3/6 of full dose Days 13-16: 4/6 of full dose Days 17-20: 5/6 of full dose Days 21 and later: full dose
Optimized Oral Peptide Delivery
Responses may vary between individuals, and appropriate medical supervision is recommended when exploring peptide-based therapies
